Chinese Health Tech Giant Delays US IPO Amid DiDi Fallout
Hong Kong To Take Up Slack?
Big data player and “Flatiron of China” is putting off its plans to go public amid regulatory scrutiny over DiDi and other companies listed in the US, but biotech firms need to worry less, says one investor.
You may also be interested in...
Billed as BridgeBio in China, US-based and China-oriented biotech LianBio breaks a long hiatus in US listing for Chinese biotechs.
The latest developments around data security and protection signal the need for rigorous implementation of procedures and potential significant cost increases for pharma and other companies operating in China.
In their latest charm offensive, Chinese regulators issue policies clearly designed to encourage the import of innovative drugs from overseas and better serve foreign drug makers already operating in the country.